How to Turning Science into 100x Returns: The Gene Therapy Blueprint from Lab to NYSE

Professor Wei-Wei Zhang, MD PhD
Nov 9 Keynote: 2:00 PM
Theme: From Lab to Global Market: Building Gene Therapy’s Future

Outline:

  1. The Dawn: Gendicine’s development journey, key challenges, and clinical impact.
  2. Ecosystem: Strategic “Three-Arrow” approach: pioneering drugs, innovative therapies, and capital leverage.
  3. Future: Gene therapy’s potential in oncology/rare diseases, current challenges/opportunities, and advice for innovators.
Nov 11 Roundtable: 10:30 AM
Theme: Precision Medicine Collaboration: Science, Capital, Industry

Role: Pioneer scientist-entrepreneur sharing end-to-end translation experience.Discussion Points:

  1. Collaboration Necessity: Multidisciplinary integration for breakthrough innovation.
  2. Practical Challenges: Overcoming regulatory, technical, and commercial hurdles; managing global teams.
  3. China’s Future: Enhancing global competitiveness and advice for biotech entrants.
3 Reasons You Must Attend This Speech:
  1. Decode the Translation Puzzle – Hear him personally recount how he turned a research paper into the first gene therapy drug, avoiding the “valley of death” that 90% of scientists fall into.
  2. Seize the Trillion-Dollar Track – Gain his precise predictions on gene therapy’s biggest breakthroughs in the next 3 years and get ahead in developing next-generation treatments.
  3. Master the Capital Engine – Learn how he used the “Three-Arrow Strategy” to raise $300 million and drive his company’s valuation to a 100x growth.
What You Will Take Away:
  1. The key decision-making framework for sciontists transitioning into antronronours
  2. 6 indicators to evaluate the commercial potential of any gene therapy project
  3. Potential opportunities to connect with the global top-tier biotech investment community
Ideal For:
  1. Research professionals looking to start their own ventures
  2. Investors seeking hard-tech projects
  3. Pharmaceutical corporate strategy leaders
  4. Entrepreneurs eager to capitalize on the biotech